BioDlink International Co Ltd, listed on the Hong Kong Stock Exchange (stock code 1875.HK), is a fully integrated Contract Development and Manufacturing Organisation that supports clients from early discovery through to commercial-scale supply of biologic therapies. Founded in 2010 and headquartered in Suzhou, China, the company combines advanced process development with large-scale GMP manufacturing capacity. Its technical expertise covers monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), fusion proteins and other bioconjugates. The organisation emphasises quality, regulatory compliance and global standards, supporting clients across Asia, Europe and the Americas through a streamlined platform and infrastructure built for complex biologics.

Key products and services

• End-to-end biologics development services (process development, analytical development, CMC support).
• Commercial-scale GMP manufacturing of biologic therapies including mAbs, bispecifics and ADCs.
• Technology transfer, scale-up and commercial supply for complex bioconjugates.
• Quality management and regulatory support for global markets (China, US, EU).
• Flexible CDMO partnering model for biopharmaceutical innovators and emerging biotech companies.

With its globally certified manufacturing platforms and deep technical domain in large-molecule biologics, BioDlink positions itself as a strategic partner for biopharmaceutical companies looking to bring next-generation therapies to market. Its integrated service model, supporting development through commercialisation, enables clients to navigate the complexities of biologic drug supply chains with agility and confidence.